Protective specific immunity induced by doxorubicin plus TNF-α combination treatment of EL4 lymphoma-bearing C57BL/6 mice

International Journal of Cancer

Volumn 87, Issue 1, 2000, Pages 101-109

  Ehrke, M Jane ^a   Verstovšek, Srdan ^a,b   Maccubbin, Darbie L ^a,c   Ujhǎzy, Peter ^a,d   Zaleskis, Gintaras ^a,e   Berleth, Erica ^a   Mihich, Enrico ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WILLIAM PATERSON UNIVERSITY   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; KILLER CELLS, LYMPHOKINE-ACTIVATED; KINETICS; LYMPHOMA; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SPLEEN; THYMUS GLAND; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034129921     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000701)87:1<101::AID-IJC15>3.0.CO;2-B     Document Type: Article

References (30)

1. BUDD, R., CEROTTINI, J., HORVATH, C., BRON, C., PEDRAZZINI, T., HOWE, R., and MACDONALD, H., Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J. Immunol., 138, 3120-3129 (1987).
2. CARMOSINO, L., DIBENEDETTO, A., and FEFFER, S., Thymic hyperplasia following successful chemotherapy: a report of two cases and review of the literature. Cancer, 56, 1526-1528 (1985).
3. CHOYKE, P.L., ZEMAN, R.K., GOOTENBERG, J.E., GREENBERG, J.N., HOFFER, F., and FRANK, J.A., Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. Amer. J. Roentgenol., 149, 269-272 (1987).
4. COHEN, J.J., Programmed cell death in the immune system. Adv. Immunol., 50, 55-85 (1991).
5. DUTTON, R.W., BRADLEY, L.M., and SWAIN, S.L., T cell memory. Ann. Rev. Immunol., 16, 201-223 (1999).
6. EGGERMONT, A.M., TNFα in isolated perfusion systems: success in the limb, developments for the liver: credits, debits and future perspectives. Anticancer Res., 18, 3899-3906 (1998).
7. EHRKE, M.J., VERSTOVŠEK, S., KRAWCZYK, C.M., UJHÁZY, P., ZALESKIS, G., MACCUBBIN, D.L., and MIHICH, E., Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int. J. Cancer, 63, 463-471 (1995).
8. EHRKE, M.J., VERSTOVSEK, S., POCCHIARI, S.K., KRAWCZYK, C.M., UJHÁZY, P., ZALESKIS, G., MACCUBBIN, D.L., MEER, J.M., and MIHICH, E. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculum. Int. J. Cancer, 76, 579-586 (1998a).
9. EHRKE, M.J., VERSTOVŠEK, S., UJHÁZY, P., MEER, J.M., EPPOLITO, C., MACCUBBIN, D.L., and MIHICH, E., Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol. Immunother., 45, 287-298 (1998b).
10. EHRKE, M.J., VERSTOVŠEK, S., ZALESKIS, G., HO, R.L.X., UJHÁZY, P., MACCUBBIN, D.L., and MIHICH, E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol. Immunother., 42, 221-230 (1996).
11. FELESZKO, W., BALKOWIEC, E.Z., SIEBERTH, E., MARCZAK, M., DABROWSKA, A., GIERMASZ, A., CZAJKA, A., and JAKOBISIAK, M., Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int. J. Cancer, 81, 560-567 (1999).
12. GATANAGA, T., NOGUCHI, K., TANABE, Y., INAGAWA, H., SOMA, G.-I., and MIZUNO, D., Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNFα in vivo. J. Biol. Response Modif., 8, 278-286 (1989).
13. HO, R.L.X., MACCUBBIN, D., ZALESKIS, G., KRAWCZYK, C, WING, K., MIHICH, E., and EHRKE, M.J., Development of a safe and effective Adriamycin plus interleukin 2 therapy against both Adriamycin-sensitive and -resistant lymphomas. Oncol. Res., 5, 373-381 (1993a).
14. HO, R.L.X., MACCUBBIN, D., UJHÁZY, P., ZALESKIS, G., EPPOLITO, C., MIHICH, E., and EHRKE, M.J., Immunological responses critical to the therapeutic effects of Adriamycin plus interleukin 2 in C57B1/6 mice bearing syngeneic EL4 lymphoma. Oncol. Res., 5, 363-372 (19936).
15. KRAWCZYK, C.M., VERSTOVŠEK, S., UJHÁZY, P., MACCUBBIN, D., and EHRKE, M.J., Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol. Immunother., 40, 347-357 (1995).
16. KURODA, K., MIYATA, K., SHIKAMA, H., KAWAGOE, T., NISHIMURA, K., TAKEDA, K., SAKAE, N., and KATO, M., Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int. J. Cancer, 63, 152-157 (1995).
17. LEJEUNE, F.J., RUEGG, C., and LIENARD, D., Clinical applications of TNFα in cancer. Curr. Opin. Immunol., 10, 573-580 (1998).
18. MACCUBBIN. D.L., MACE, K.F., EHRKE, M.J., and MIHICH, E., Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res., 49, 4216-4224 (1989).
19. MACCUBBIN, D.L., WING, K.R., MACE, K.F., HO, R.L., EHRKE, M.J., and MIHICH, E., Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res., 52, 3572-3576 (1992).
20. MANUSAMA, E.R., NOOIJEN, P.T., TEN HAGEN, T.L., VAN DER VEEN, A.H., DE VRIES, M.W., DE WILT, J.H., VAN IJKEN, M.G., MAROUET, R.L., and EGGERMONT, A.M., Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. Semin. surg. Oncol., 14, 232-237 (1998).
21. OKA, M., HAZAMA, S., YOSHINO, S., SHIMODA, K., SUZUKI, M., SHIMIZU, R., YANO, K., NISHIDA, M., and SUZUKI, T., Intraarterial combined immunochemistry for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol. Immunother., 38, 194-200 (1994).
22. SCULIER, J.P., and BODY, J.J., Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNFα. Ann. Oncol., 2, 141-144 (1991).
23. SIMMONDS, P., SILBERSTEIN, M., and MCKENDRICK, J., Thymic hyperplasia in adults following chemotherapy for malignancy. Aust. N.Z. J. Med., 23, 264-267 (1993).
24. SONNEVELD, P., VAN LOM, K., KAPPERS-KLUNNE, M., PRINS, M.E., and ABELS, J., Clinicopathological diagnosis and treatment of malignant histiocytosis. Br. J. Haematol., 75, 511-516 (1990).
25. TEN HAGEN, T.L., and EGGERMONT, A.M., A rat extremity soft tissue sarcoma model for the study of systemic treatment with stealth liposome-encapsulated tumor necrosis factor-α and cytotoxic agents. Adv. Drug Delivery Rev., 24, 245-256 (1997).
26. UJHÁZY, P., CHEN, Y.-F., FREDERICKS, W., HO, R.L.X., MIHICH, E., BAKER, R.M., and EHRKE, M.J., The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model. Cancer Comm., 2, 181-188 (1990).
27. YOSHIDA, J., WAKABAYASHI, T., MIZUNO, M., SUGITA, K., YOSHIDA, T., HORI, S., MORI, T., SATO, T., KARASHIMA, A., and KURISU, K., Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J. Neurosurg., 77, 78-83 (1992).
28. ZALESKIS, G., BERLETH, E., EHRKE, M.J., and MIHICH, E., Doxorubicin induced DNA degradation in murine thymocytes. Mol. Pharmacol., 46, 901-908 (1994a).
29. ZALESKIS, G., HO, R.L.X., DIEGELMAN, P., MACCUBBIN, D., UJHÁZY, P., MIHICH, E., and EHRKE, M.J., Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol. Res., 6, 183-194 (1994b).
30. ZALESKIS, G., VERSTOVŠEK, S., TZAI, T.S., MIHICH, E., and EHRKE, M.J., Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol. Res., 7, 307-315 (1995).